GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Equity Group A/S (OCSE:PEG) » Definitions » ROE % Adjusted to Book Value

Pharma Equity Group A/S (OCSE:PEG) ROE % Adjusted to Book Value : -6.99% (As of Mar. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Pharma Equity Group A/S ROE % Adjusted to Book Value?

Pharma Equity Group A/S's ROE % for the quarter that ended in Mar. 2024 was -81.14%. Pharma Equity Group A/S's PB Ratio for the quarter that ended in Mar. 2024 was 11.61. Pharma Equity Group A/S's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was -6.99%.


Pharma Equity Group A/S ROE % Adjusted to Book Value Historical Data

The historical data trend for Pharma Equity Group A/S's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Equity Group A/S ROE % Adjusted to Book Value Chart

Pharma Equity Group A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -22.90 -73.66 28.63 -57.62 -5.12

Pharma Equity Group A/S Quarterly Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.19 -2.84 -4.00 -10.19 -6.99

Competitive Comparison of Pharma Equity Group A/S's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Pharma Equity Group A/S's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma Equity Group A/S's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Equity Group A/S's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Pharma Equity Group A/S's ROE % Adjusted to Book Value falls into.



Pharma Equity Group A/S ROE % Adjusted to Book Value Calculation

Pharma Equity Group A/S's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-57.92% / 11.32
=-5.12%

Pharma Equity Group A/S's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-81.14% / 11.61
=-6.99%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharma Equity Group A/S ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Pharma Equity Group A/S's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharma Equity Group A/S (OCSE:PEG) Business Description

Traded in Other Exchanges
N/A
Address
Slotsmarken 18, 2.th., Horsholm, DNK, DK-2970
Pharma Equity Group A/S is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develops technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement.